| Active ingredient (INN) | Palivizumab |
|---|---|
| Brand names | Synagis |
| Therapeutic category | Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper |
| Controlled substance | No |
|---|
| Marketing-authorisation holders | AstraZeneca Pty Ltd |
|---|
| Registrations on file | 2 |
|---|
| Patient information leaflet (PIL) | Not on file |
|---|
| Summary of product characteristics (SPC) | Not on file |
|---|
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| SYNAGIS palivizumab | 100 mg | — | 🇦🇺 AU | AstraZeneca Pty Ltd | Active |
| SYNAGIS palivizumab | 50 mg | — | 🇦🇺 AU | AstraZeneca Pty Ltd | Active |